MAIA Biotechnology, Inc.

MAIA

AMEX

Healthcare

Biotechnology

Chicago, IL, US13 employeesMAIABiotech.com

$1.34

-0.01(-0.37%)

Mkt Cap $52M

$0.87

$2.95

52-Week Range

At a Glance

AI-generated

MAIA Biotechnology, Inc.

8-K

MAIA Biotechnology, Inc. awarded one-time bonus payments of $312,610 to CEO Vlad Vitoc and $50,000 to Head of Finance Jeffrey Himmelreich on March 31, 2026, in connection with the company’s recent capital raise.

$52M

Market Cap

—

Revenue

—

Net Income

Employees13

Fundamentals

How The Business Makes Money

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Apr 1, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** On March 27

Material Agreement

Mar 3, 2026

. Entry into a Material Definitive Agreement. On March 2, 2026, MAIA Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriti

Other Event

Mar 30, 2026

** **Other Events.** On March 31, 2026, MAIA Biotechnology, Inc. (the “Company”) issued a press release entitled “MAIA Biotechnology Reports Overall Survival Ex

Regulation FD

Mar 26, 2026

Regulation FD Disclosure. MAIA Biotechnology, Inc., (the “Company”) has prepared a poster (the “Poster”) entitled “Sustained Response and Long-Term Therapeutic

Other Event

Feb 23, 2026

Other Events. On February 24, 2026, MAIA Biotechnology, Inc. (the “Company”) issued a 2026 Letter to Shareholders detailing the Company’s development pipeline.

Peer Companies

Company	Price	Change	Market Cap	P/E
ELUTElutia Inc.	$1.18	+8.26%	$50M	0.9
ANVSAnnovis Bio, Inc.	$2.27	+7.31%	$45M	-2.1
PYPDPolyPid Ltd.	$4.38	-0.34%	$45M	-2.5
RNXTRenovoRx, Inc.	$1.02	+5.15%	$37M	-3.7
VERUVeru Inc.	$2.30	+1.32%	$37M	-2.4
CELUCelularity Inc.	$1.34	+2.29%	$32M	-0.4
TVRDTvardi Therapeutics, Inc.	$3.03	+1.00%	$28M	-2.4
LTRNLantern Pharma Inc.	$1.59	+12.32%	$18M	-1.3

Analyst View

Company Profile

CIK0001878313

ISINUS5526411021

CUSIP552641102

Phone312 416 8592

Address444 West Lake Street, Chicago, IL, 60606, US

SEC EDGAR